ES2177644T3 - Procedimiento para la resolucion de etodolac utilizando derivados de glucamina. - Google Patents

Procedimiento para la resolucion de etodolac utilizando derivados de glucamina.

Info

Publication number
ES2177644T3
ES2177644T3 ES95915264T ES95915264T ES2177644T3 ES 2177644 T3 ES2177644 T3 ES 2177644T3 ES 95915264 T ES95915264 T ES 95915264T ES 95915264 T ES95915264 T ES 95915264T ES 2177644 T3 ES2177644 T3 ES 2177644T3
Authority
ES
Spain
Prior art keywords
etodolac
pct
resolution
glucamine
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95915264T
Other languages
English (en)
Inventor
Brian Michael Adger
Ulrich Conrad Dyer
Martin Woods
John Francis Paul Andrews
Helen Frances Baker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sosei R&D Ltd
Original Assignee
Arakis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9407225A external-priority patent/GB9407225D0/en
Priority claimed from GBGB9501455.1A external-priority patent/GB9501455D0/en
Application filed by Arakis Ltd filed Critical Arakis Ltd
Application granted granted Critical
Publication of ES2177644T3 publication Critical patent/ES2177644T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SALES DE GLUCAMINA O N-(C 1-4 ALQUIL)GLUCAMINA (FORMULA 1) CON S-ETODOLACO, (FORMULA 2) PREFERIBLEMENTE LA SAL MEGLUMINA, SON PARTICULARMENTE APROPIADOS PARA PRODUCIR EFECTOS ANALGESICOS RAPIDOS. ESTAS SALES PUEDEN SER PREPARADAS MEDIANTE LA RESOLUCION DE EDOTOLACO RACEMICO USANDO COMO AGENTE DE RESOLUCION GLUCAMINA O UNA N-(C{SUB,1-4}ALQUIL)GLUCAMINA. ADEMAS, SALES DE S-ETODOLACO SOLUBLES EN AGUA EN GENERAL PUEDEN SER USADAS EN LA FABRICACION DE MEDICAMENTOS PARA EL USO EN ANALGESIA DE EFECTO RAPIDO Y EN EL TRATAMIENTO DE DOLORES CRONICOS, Y SON PARTICULARMENTE APROPIADOS PARA FORMULACIONES DE LIBERACION SOSTENIDA
ES95915264T 1994-04-12 1995-04-11 Procedimiento para la resolucion de etodolac utilizando derivados de glucamina. Expired - Lifetime ES2177644T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9407225A GB9407225D0 (en) 1994-04-12 1994-04-12 Chiroscience limited
GBGB9501455.1A GB9501455D0 (en) 1995-01-25 1995-01-25 Analgesic agent and its use

Publications (1)

Publication Number Publication Date
ES2177644T3 true ES2177644T3 (es) 2002-12-16

Family

ID=26304688

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95915264T Expired - Lifetime ES2177644T3 (es) 1994-04-12 1995-04-11 Procedimiento para la resolucion de etodolac utilizando derivados de glucamina.

Country Status (9)

Country Link
US (1) US5811558A (es)
EP (1) EP0755398B1 (es)
JP (1) JPH09511516A (es)
AT (1) ATE221533T1 (es)
AU (1) AU2220695A (es)
DE (1) DE69527617T2 (es)
ES (1) ES2177644T3 (es)
NO (1) NO964346L (es)
WO (1) WO1995027713A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574183A (en) * 1995-01-24 1996-11-12 Albemarle Corporation Preparation of optically active aliphatic carboxylic acids
US6399093B1 (en) 1999-05-19 2002-06-04 Advanced Medical Instruments Method and composition to treat musculoskeletal disorders
US7361680B2 (en) * 1999-07-23 2008-04-22 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7151100B1 (en) 1999-07-23 2006-12-19 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7129262B2 (en) * 1999-07-23 2006-10-31 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US6545034B1 (en) 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US7105560B1 (en) 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
GB0007239D0 (en) * 2000-03-24 2000-05-17 Nycomed Imaging As Use
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
US20030232794A1 (en) * 2001-06-26 2003-12-18 Cottam Howard B. Use of STAT-6 inhibitors as therapeutic agents
US7601846B2 (en) * 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
GB0206505D0 (en) * 2002-03-19 2002-05-01 Euro Celtique Sa Pharmaceutical combination
WO2004026116A2 (en) * 2002-09-19 2004-04-01 The Regents Of The University Of California Use of etodoclac to treat hyperplasia
ITMI20031471A1 (it) 2003-07-18 2005-01-19 Chemi Spa Processo per la racemizzazione dell'acido etodolico
PT3056492T (pt) 2004-10-08 2021-12-27 Abbvie Inc Sal de meglumina e formas cristalinas do mesmo de um fármaco (delafloxacina)
CA2603783C (en) * 2005-04-11 2014-11-18 Abbott Laboratories Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs
ITMI20060894A1 (it) 2006-05-05 2007-11-06 Univ Catania Ciclodestrine funzionalizzate con etodolac come agenti di rilascio sito specifico
CA2653941C (en) 2006-05-31 2013-01-08 The Regents Of The University Of California Substituted amino purine derivatives and uses thereof
CN102850204B (zh) * 2011-06-29 2015-08-19 徐州医学院 一种(s)-2-芳基丙酸类非甾体抗炎药的拆分方法
WO2013169218A1 (en) 2012-05-08 2013-11-14 Mahmut Bilgic Pharmaceutical compositions of s-etodolac

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501899A (en) * 1983-08-16 1985-02-26 American Home Products Corporation Resolution of (+)-1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid using cholesteryl aniline
US4520203A (en) * 1983-08-16 1985-05-28 American Home Products Corporation Resolution of (±)-1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid using cinchonine
US4544757A (en) * 1984-02-16 1985-10-01 American Home Products Corporation Process for the resolution of pyrano[3,4-b]indole-1-acetic acids
IT1207994B (it) * 1986-01-03 1989-06-01 Therapicon Srl Sali idrosulubili di composti adattivita' antiinfiammatoria ed analgesica, loro preparazione ed utilizzo in composizioni farmaceutiche.
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
EP0408496A3 (en) * 1989-07-12 1992-07-01 Ciba-Geigy Ag Solid dosage form for pharmaceutical substances
US5256293A (en) * 1991-09-20 1993-10-26 Research Corporation Technologies, Inc. Separation of enantiomers of non-steroidal anti-inflammatory drugs and chiral selector therefor

Also Published As

Publication number Publication date
EP0755398B1 (en) 2002-07-31
DE69527617T2 (de) 2003-04-10
EP0755398A1 (en) 1997-01-29
WO1995027713A1 (en) 1995-10-19
US5811558A (en) 1998-09-22
DE69527617D1 (de) 2002-09-05
JPH09511516A (ja) 1997-11-18
NO964346D0 (no) 1996-10-11
ATE221533T1 (de) 2002-08-15
AU2220695A (en) 1995-10-30
NO964346L (no) 1996-12-11

Similar Documents

Publication Publication Date Title
ES2177644T3 (es) Procedimiento para la resolucion de etodolac utilizando derivados de glucamina.
BR9506305A (pt) Aparelho e processo para preparação de formas sólidas com desprendimento controlado do ingrediente ativo
MX9302214A (es) Derivados de taxol y proceso para su preparacion
EA199800857A1 (ru) Композиция для снятия боли и способ снятия боли
ES2173194T3 (es) Procedimiento de racemizacion utilizado para la preparacion de levobupivacaina y sus analogos.
AR042345A2 (es) Un procedimiento para la preparacion de una composicion farmaceutica para el tratamiento de aterosclerosis que contiene 8.9 - dehidroesterona o sus sales de la misma
PT99794A (pt) Processo para a preparacao de novas piperazinas 1,4-dissubstituidas
GEP20033044B (en) Method for Treating Atherosclerosis
PT93959A (pt) Processo para a preparacao de derivados de sacarina uteis como inibidores proteoliticos de enzima
ES2187566T3 (es) Formulaciones farmaceuticas mejoradas que contienen ibuprofeno y codeina.
HK1014927A1 (en) Method of resolving racemic mixtures
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
ES2126313T3 (es) Hidrolisis enzimatica de los 4-metiltiobutironitrilos.
NO308661B1 (no) FremgangsmÕte for fremstilling av 5-acetamido-2,3,4,5- tetradeoksy-4-guanidino-D-glycero-D-galakto-non-2-enopyranosonsyre og en forbindelse til bruk ved fremgangsmÕten
SE9501808D0 (sv) New process
NO973366L (no) Fremgangsmåte for behandling av multippel sklerose
DE69607113D1 (de) Verfahren zur Racemisierung von optisch aktiven 1-Phenylethylamin-Derivaten
ES2163001T3 (es) Nuevos derivados de borneol, procedimiento para su preparacion y su utilizacion farmaceutica.
NO990159D0 (no) FremgangsmÕte for fremstilling av enantiomerisk anrikede N-acylazetidin-2-karboksylsyrer
NZ333443A (en) Method of treating a plant disease comprising applying oxi-fulvic acid an acitve ingredient
ES2061712T3 (es) Nuevos derivados sustituidos de 20,21-dinoreburnamenina, su procedimiento de preparacion y los nuevos productos intermedios asi obtenidos, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
ES2145292T3 (es) Procedimiento bacteriano para la resolucion de cis-dioles racemicos.
PT854862E (pt) Processo para a preparacao de um aminoacido activado
ES2056657T3 (es) Derivado de la beta-fenilisoserina, su preparacion y su empleo.
AR023332A1 (es) Compuestos derivados de benzamida sustituidos, proceso para su preparacion, formulaciones farmaceuticas que los comprenden, y metodo de tratamiento